2 McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in
rhesus macaques. Nature 2021; 590: 630–34. 3 Yu J, Tostanoski LH, Peter L, et al. DNA …

1 Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute
coronary syndromes in patients presenting without persistent ST-segment elevation. Eur …

Erratum for Zeng et al., â•œNeutralization of SARS-CoV-2 Variants of Concern Harboring
Q677Hâ•š Page 1 Erratum for Zeng et al., “Neutralization of SARS-CoV-2 Variants of Concern …

Importance Although P2Y12 inhibitor monotherapy after a minimum period of dual
antiplatelet therapy (DAPT) is a well-known way to reduce the risk of bleeding after …

6. Mallapaty, S. Nature 591, 353–354 (2021). 7. Chen, Y. et al. PLoS ONE 5, e11926 (2010).
8. Xiao, Y. et al. Postgrad. Med. J. https://doi. org/10.1136/postgradmedj-2021-140853 …

Background Over the past decade, major society guidelines have recommended the use of
newer P2Y12 inhibitors over clopidogrel for those undergoing percutaneous coronary …

Background Conflicting results were reported by randomized controlled trials (RCTs)
exploring guided therapy (GT) with anti-P2Y12 drugs in patients undergoing percutaneous …

Background P2Y12 inhibitor medications are critical following percutaneous coronary
intervention (PCI); however, adherence remains suboptimal. Our objective was to assess the …

Background To compare the prescription rates, safety, and efficacy of contemporary P2Y 12
inhibitors in acute coronary syndrome (ACS) patients following percutaneous coronary …

Background Nirmatrelvir with ritonavir (nirmatrelvir/r) is an oral antiviral COVID-19 treatment.
We report its efficacy to shorten time to sustained alleviation and resolution of COVID-19 …